OLANZAPINE ODT TEVA ® 5 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

OLANZAPINE 5 MG

Commercializzato da:

SALOMON,LEVIN & ELSTEIN LTD

Codice ATC:

N05AH03

Forma farmaceutica:

TABLETS ORODISPERSIBLE

Via di somministrazione:

PER OS

Prodotto da:

TEVA OPERATIONS POLAND SP.ZO.O

Gruppo terapeutico:

OLANZAPINE

Indicazioni terapeutiche:

Acute and maintenance treatment of schizophrenia. Olanzapine ODT Teva is indicated for the management of the manifestations of psychotic disorders. Olanzapine ODT Teva is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. Prevention of recurrence in Bipolar Disorder : In patients whose manic episode has responded to olanzapine treatment Olanzapine ODT Teva is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder: The combination of Olanzapine ODT Teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Data dell'autorizzazione:

2011-05-01